Ney Carter Borges: Mechanistic Insights and Clinical Cardiovascular Outcomes of GLP-1 Receptor Agonists
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Florian Kahles et al, published in The Journal of Clinical Investigation:
“GLP-1 and the cardiovascular system
Mechanistic Insights and Clinical Cardiovascular Outcomes
Preclinical Cardiovascular Mechanisms
Atherosclerosis
- Decreases Vascular inflammation
- Decreases Systemic inflammation
- Decreases Monocyte and macrophage activation
- Decreases Foam cell formation
- Decreases Bone marrow hematopoiesis
- Increases Fibrous cap thickness
- Decreases Plaque size
- Effects largely independent of LDL-C, blood pressure, and body weight
Experimental models (ApoE−/− and LDLr−/− mice) consistently demonstrate plaque stabilization and reduced atherogenesis through anti-inflammatory and vascular protective mechanisms
Heart Failure and Myocardial Protection
- Decreases Ischemia–reperfusion injury
- Decreases Cardiomyocyte apoptosis
- Decreases Cardiac and systemic inflammation
- Increases Myocardial glucose utilization
- Increases Cardiac output during ischemic stress
- Decreases Hypertrophy and fibrosis (HFpEF models)
- Activation of PI3K/Akt, AMPK, PKC/S100A9 pathways
GLP-1R agonism improves post-MI survival and LV function across murine, porcine, and canine models
Major Cardiovascular Outcome Trials (CVOTs)
3-Point MACE Reduction (CV death, MI, Stroke)
Meta-analysis of 11 CVOTs
- HR 0.86 (95% CI 0.80–0.93)
- Relative Risk Reduction (RRR): 14%
- NNT ≈ 65
- p < 0.001
SELECT Trial (Obesity without T2D)
- HR 0.80 (95% CI 0.72–0.90)
- 20% RRR in MACE
- 9% weight loss
- 17,500 participants
SOUL Trial (Oral Semaglutide)
- HR 0.86 (95% CI 0.77–0.96)
- 14% RRR in MACE
- p = 0.006
Heart Failure Outcomes
- Decreases Hospitalization for HF: HR 0.86 (95% CI 0.79–0.93)
- FLOW trial (T2D + CKD):
- Composite HF events: HR 0.73 (95% CI 0.62–0.87)
- CV death: HR 0.71 (95% CI 0.56–0.89)
Clinical Interpretation
GLP-1 receptor agonists provide:
- Robust ASCVD risk reduction
- HFpEF symptom and functional improvement
- Modest BP and lipid improvements (insufficient alone to explain benefit)
- Anti-inflammatory and plaque-stabilizing effects
- Cardioprotection independent of glycemic control alone
The cardiovascular benefit emerges after 12–18 months, suggesting structural plaque modification rather than acute hemodynamic effects.
GLP-1 receptor agonists have evolved from glucose-lowering agents into cardiometabolic protective therapies with consistent reductions in MACE and meaningful benefits in heart failure—particularly HFpEF. Preclinical mechanistic data strongly align with clinical outcomes, establishing GLP-1–based therapy as a cornerstone of cardiovascular risk reduction in T2D, CKD, and obesity.”
Title: GLP-1 and the cardiovascular system
Authors: Florian Kahles, Andreas L. Birkenfeld, Nikolaus Marx
Read the Full Article on The Journal of Clinical Investigation.
Find more posts featuring Ney Carter Borges on Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026